SCHEMBL10104437

SCHEMBL10104437

Cc1cc(CN(C)C)c(Cl)c(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 10/20 0.42
HTR2A P28223 4/20 0.42
KCNH2 Q12809 4/20 0.42
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
HSPA5 P11021 1/20 0.36
RAPGEF4 Q8WZA2 1/20 0.36
CYP2C19 P33261 2/20 0.35
CYP2C9 P11712 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HIF1A Q16665 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104451 0.85 NOS3 (0.35) SLC6A4HTR2AKCNH2NOS3NOS1
SCHEMBL10663593 0.83 HSPA5 (0.46) SLC6A4HTR2AKCNH2CYP2D6HSPA5
SCHEMBL10104503 0.82 CYP3A4 (0.39) SLC6A4HTR2AKCNH2CYP3A4CYP2D6
SCHEMBL10767971 0.79 HSPA5 (0.38) SLC6A4HTR2AKCNH2CYP2D6HSPA5
SCHEMBL10104527 0.79 HSPA5 (0.42) SLC6A4HTR2AKCNH2CYP2D6HSPA5
SCHEMBL10104537 0.77 SLC6A4 (0.37) SLC6A4HTR2AKCNH2CYP3A4CYP2D6
SCHEMBL15517270 0.77 RAPGEF4 (0.42) HTR2ACYP3A4CYP2D6HSPA5RAPGEF4
SCHEMBL13960088 0.75 SLC6A4 (0.46) SLC6A4HTR2AKCNH2CYP3A4CYP2D6
SCHEMBL10104436 0.74 RORC (0.46) NOS3NOS1NOS2KDM4EMEN1
SCHEMBL10104319 0.72 RAPGEF4 (0.33) RAPGEF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 SLC6A4 4238/4885HTR2A 4089/4885KCNH2 2711/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 SLC6A4 1991/4885HTR2A 2935/4885KCNH2 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.